Connect with us

Media & Technology

Major Run on XMET (Xxstream Entertainment) as Wei Tian Buys out Lazar Custodianship/SPAC RM Player

Published

on

XMET (Xxstream Entertainment) is gearing up and heating up in recent months skyrocketing out of the triple zeroes and emerging well into pennyland with recent highs of $0.02 per share.  The stock has been under heavy accumulation recently and volume has picked up substantially with XMET regularly trading several 100 million shares per day and topped $2 million in dollar volume on Friday alone. XMET is a custodianship/SPAC from David Lazar. Reverse Merger stocks are proving to be more explosive than biotech and XMET has all the markings of a coming Reverse Merger and powerful runner.

XMET BRAND NEW ARTICLE PUBLISHED ON MICROCAPDAILY 3.7.2021

XMET started moving at the beginning of December out of the triple zeroes and Microcapdaily reported on XMET on December 1 when the stock was still sub $0.001. Since than XMET has risen dramatically as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than XMET has.  

The time could not be better for XMET to make a real powerhouse move to a whole new dimension like so many other penny stocks are these days. XMET origins as a David Lazar, OTC SPAC’s/CUSTODIAN Plays is significant as many of these plays have been hugely successful making powerful sustained runs indicative of a clean share structure. David Lazar custodianship/SPAC RM deals have been so successful in fact they have even spawned the message board; David Lazar, OTC SPAC’s/CUSTODIAN Plays on Investorshub.com. On December 9, 2020, as a result of a private transactions, 100,000,000 shares of Series A Preferred Stock of XMET were transferred from Custodian Ventures, LLC to Wei Tian. As a result, the Purchaser became an approximately 93% holder of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $220,000. The source of the cash consideration for the Shares was personal funds of the Purchaser. In connection with the transaction, David Lazar released the Company from all debts owed to him. Wei Tian is a certified Futures Advisor, Securities Analyst, and Market Risk Analyst. We Tian worked at Morgan Stanley, in the Department of Global Capital Markets in HK, at China Futures Co., Ltd., in the Department of Research, and at China Securities Co., Ltd., in the Department of Investment Banking/Research. Wei Tian participated and issued the Deutsche Bank Subprime Mortgage Bonds Derivatives Plan, participate and issued the HSBC trust asset-backed securitization Plan, and participated in multiple IPOs. Wei Tian has been appointed as a Chief Executive Officer, President, Secretary, Treasurer and Chairman of Board of Directors of the Company.  

XMET (Xxstream Entertainment) is a clean shell that was dormant for many years but has come to life as the Company recently filed its quarterly report becoming Pink Current on OtcMarketsXXStream, Inc. was formed on May 21, 2005, with an initial business plan to offer a new type of entertainment portal on the web that is built from the ground up for today’s always on high bandwidth 18–35-year-old demographic. The club was intended to be the first portal online that would blend online and offline entertainment in ways that leverage the synergies of the real and virtual worlds in unique ways. The Company intended to create a new media company that would provide multi-cultural digital content for consumers in every major market segment in Europe, South America, Asia, and Mexico. Club XXStream was targeting a young global demographic, with the primary focus being 18-35 years of age, as this demographic group is affluent, technically sophisticated, and is always seeking new ways to find entertainment off and online. Club XXStream was in partnership discussions large media content and technology providers including MTV, Microsoft, Macromedia, Real Networks, Yahoo, AOL/Time Warner  

XMET was created in 2006 as a dividend to trap the NS on PYCT, it never had a biz, no debt, never traded, it was grey sheet, until David Lazar got it up listed to the OTC pink venue, and was granted custodianship. Mario Pino former CEO has died recently, and clearly has no connection or influence on XMET.  

On July 20, 2020, Custodian Ventures, LLC was appointed as the custodian of the Company by the Eighth Judicial Court of Nevada pursuant to Case No. A-20-816267-B. David Lazar is a private investor and since February of 2018, Mr. Lazar has been the managing member of Custodian Ventures LLC, where he specializes in assisting distressed public companies. Since March 2018, David has acted as the managing member of Activist Investing LLC, which specializes in active investing in distressed public companies. David has a diverse knowledge of financial, legal and operations management; public company management, accounting, audit preparation, due diligence reviews, and SEC regulations.  

There is a great article on OTC SPAC’s/CUSTODIAN Plays here.

Image result for David Lazar, OTC SPAC’s/CUSTODIAN Plays

In recent years there have been a number of hugely successful David Lazar custodianship/SPAC RM deals that have even spawned the message board; David Lazar, OTC SPAC’s/CUSTODIAN Plays on Investorshub.com.  

Investor Sentiment in XMET is high. On Decmeber 1 the same day Microcapdaily first covered XMET Clay Trader posted a technical analysis on XMET on youtube.

https://twitter.com/Jdog651/status/1359578336645636096

To get an inside look at XMET Subscribe to Microcapdaily.com immediately by entering your Email below

XMET

Microcapdaily has reported on XMET before. On December 1, 2020 just as XMET was rising up out of the triple zeroes Microcapdaily reported its article: Custodianship/SPAC; the Rise of Xxstream Entertainment (OTCMKTS: XMET) Stating: “Xxstream Entertainment (OTCMKTS: XMET) is another exciting RM play getting noticed by penny stock speculators and trading big volume topping $4 million + per day in dollar volume. XMET is another custodianship/SPAC from David Lazar. Reverse Merger stocks are proving to be more explosive than biotech and XMET has all the markings of a coming Reverse Merger. After many years of dormancy XMET has come to life filing its quarterly report becoming Pink Current on OtcMarkets. On July 20, 2020, Custodian Ventures, LLC was appointed as the custodian of the Company by the Eighth Judicial Court of Nevada pursuant to Case No. A-20-816267-B. David Lazar is a private investor and since February of 2018, Mr. Lazar has been the managing member of Custodian Ventures LLC, where he specializes in assisting distressed public companies. Since March 2018, David has acted as the managing member of Activist Investing LLC, which specializes in active investing in distressed public companies. David has a diverse knowledge of financial, legal and operations management; public company management, accounting, audit preparation, due diligence reviews, and SEC regulations. In recent years there have been a number of hugely successful David Lazar custodianship/SPAC RM deals that have even spawned the message board; David Lazar, OTC SPAC’s/CUSTODIAN Plays on Investorshub.com.  

Image result for XXSTREAM ENTERTAINMENT, INCOn December 14 XMET filed an 8k: Item 5.01 Changes in Control of Registrant. On December 9, 2020, as a result of a private transactions, 100,000,000 shares of Series A Preferred Stock, $0.001 par value per share of XXStream Entertainment, Inc., a Nevada corporation were transferred from Custodian Ventures, LLC to Wei Tian. As a result, the Purchaser became an approximately 93% holder of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $220,000. The source of the cash consideration for the Shares was personal funds of the Purchaser. In connection with the transaction, David Lazar released the Company from all debts owed to him. Other than as described below, there are no arrangements or understandings among both the former and new control persons and their associates with respect to the election of directors of the Company or other matters. The information set forth in Item 5.02 of this Form 8-K is incorporated by reference into this Item 5.01.   

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 9, 2020, the existing director and officer resigned immediately. Accordingly, David Lazar, serving as a director and an officer, ceased to be the Company’s Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and a Director. At the effective date of the transfer, Wei Tian consented to act as the new President, CEO, CFO, Treasurer, Secretary and Chairman of the Board of Directors of the Company.  

Wei Tian has a Bachelor Degree in Finance at Capital University of Economics and Business, and a Bachelor Degree in International Economy and Trade at Shandong University. Wei Tian is a certified Futures Advisor, Securities Analyst, and Market Risk Analyst. We Tian worked at Morgan Stanley, in the Department of Global Capital Markets in HK, at China Futures Co., Ltd., in the Department of Research, and at China Securities Co., Ltd., in the Department of Investment Banking/Research. Wei Tian participated and issued the Deutsche Bank Subprime Mortgage Bonds Derivatives Plan, participate and issued the HSBC trust asset-backed securitization Plan, and participated in multiple IPOs. Wei Tian has been appointed as a Chief Executive Officer, President, Secretary, Treasurer and Chairman of Board of Directors of the Company.  

On January 14 XMET filed a SEC Form 15-12G (CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.) Form 15-12G is provided by the (SEC) in reference to Sections 12(g), 13 and 15(d) of the 1934 Securities Exchange Act. The Form allows issuers to seek termination of a registered security class or suspension of duty for filing SEC mandated reports. SEC Form 15-12G releases companies of some of their reporting requirements under Sections 12(g), 12(h), 13 and 15(d) of the 1934 Securities Exchange Act. 

For More on XMET Subscribe Right Now!

XMET is gearing up and heating up in recent months skyrocketing out of the triple zeroes and emerging well into pennyland with recent highs of $0.02 per share.  The stock has been under heavy accumulation recently and volume has picked up substantially with XMET regularly trading several 100 million shares per day and topped $2 million in dollar volume on Friday alone. XMET is a custodianship/SPAC from David Lazar. Reverse Merger stocks are proving to be more explosive than biotech and XMET has all the markings of a coming Reverse Merger and powerful runner. XMET started moving at the beginning of December out of the triple zeroes and Microcapdaily reported on XMET on December 1 when the stock was still sub $0.001. Since than XMET has risen dramatically as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than XMET has. The time could not be better for XMET to make a real powerhouse move to a whole new dimension like so many other penny stocks are these days. XMET origins as a David Lazar, OTC SPAC’s/CUSTODIAN Plays is significant as many of these plays have been hugely successful making powerful sustained runs indicative of a clean share structure. David Lazar custodianship/SPAC RM deals have been so successful in fact they have even spawned the message board; David Lazar, OTC SPAC’s/CUSTODIAN Plays on Investorshub.com. On December 9, 2020, as a result of a private transactions, 100,000,000 shares of Series A Preferred Stock of XMET were transferred from Custodian Ventures, LLC to Wei Tian. As a result, the Purchaser became an approximately 93% holder of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $220,000. The source of the cash consideration for the Shares was personal funds of the Purchaser. In connection with the transaction, David Lazar released the Company from all debts owed to him. Wei Tian is a certified Futures Advisor, Securities Analyst, and Market Risk Analyst. We Tian worked at Morgan Stanley, in the Department of Global Capital Markets in HK, at China Futures Co., Ltd., in the Department of Research, and at China Securities Co., Ltd., in the Department of Investment Banking/Research. Wei Tian participated and issued the Deutsche Bank Subprime Mortgage Bonds Derivatives Plan, participate and issued the HSBC trust asset-backed securitization Plan, and participated in multiple IPOs. Wei Tian has been appointed as a Chief Executive Officer, President, Secretary, Treasurer and Chairman of Board of Directors of the Company.  We will be updating on XMET when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with XMET.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in XMET either long or short and we have not been compensated for this article.

Continue Reading
1 Comment

1 Comment

  1. fishdynqc637

    May 20, 2021 at 12:55 pm

    Hello. And Bye. Great article!

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Featured

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) Secure Partnership

Published

on

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan's proprietary target discovery platform.

TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.

Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.

All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable. 

The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable. 

Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand: 

Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.

As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.

To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.

Here are a couple of blurbs from the management team

“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”

“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”

What’s retail saying?

As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques. 

Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day.  Compared to the ~27M shares traded at the time of writing, that’s a massive shift.

We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.